PharmAthene Inc (NYSEMKT:PIP) has seen a shortfall of 45,276 shares or 3.1% in the short interest. The remaining shorts are 2.2% of the total floated shares. The net short interest, as on June 15,2016, stood at 1,416,049 shares and the stocks days to cover will be 6 by factoring in the average per day volume of 228,172 shares. On May 31,2016, 1,461,325 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
PharmAthene Inc (NYSEMKT:PIP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.30 and $2.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.42. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.39, notching a gain of 2.14% for the day. The total traded volume was 5,537,232 . The stock had closed at $2.34 on the previous day.
The company shares have rallied 35.80% from its 1 Year high price. On Apr 26, 2016, the shares registered one year high at $2.49 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $2.26 and the 200 Day Moving Average price is recorded at $1.94.
PharmAthene Inc (NYSEMKT:PIP) has climbed 8.64% in the past week and advanced 7.17% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 10.44% and the outperformance has advanced to 10.42% for the last 4 weeks period.
Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines, including SparVax, which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine, and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger, which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds, including nerve gases and pesticides, and Valortim, which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS).